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1. Introduction
1.1. Skin and melanocytes
Skin is composed of three layers: epidermis, dermis and hypodermis. The epidermis is
organized into five layers in which there are different cell types. The most important cell type
in the epidermis is the keratinocytes which constitute approximately 95 % of the total epider‐
mal cells. Melanocytes, Langerhans cells, Merkel cells and inflammatory cells form the
remaining 5 % [1]. Among these cells, the melanocytes, which are dendritic cells, are the second
most important cell type in the epidermis. They have the capacity to synthesize melanin, a skin
pigment. Melanocytes are not only found in the skin, but can also be observed in hair, eyes,
ears and central nervous system (Table 1) [2-3]. Their different localization gives them different
functions in the organism, but they all keep a common function: melanogenesis [1].
1.1.1. Skin melanocytes
Skin melanocytes are localized in the basal layer of the epidermis, at the junction of the dermis,
and their dendrites expand between keratinocytes of the next layer. These dendrites allow
melanocytes to make contact with the keratinocytes for the melanin transfer. This cell-to-cell
contact stimulates proliferation and differentiation of melanocytes due to growth factors
produced by the keratinocytes [4]. Thus, the melanosome, organelle containing melanin
pigments, can be transferred to the adjacent keratinocytes, which store the pigments, and
degrade them when they move to the skin surface [5]. When the pigments are in keratinocytes,
they give a color to the skin with a mix of other pigments such as carotenoids and hemoglobin
derivatives [6-7]. However, melanin is the principal pigment present in the skin [7] and can be
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found in two different colors: yellow/red (pheomelanin) and brown/black (eumelanin) [8].
These two types of pigment are one of the explanations for different ethnic skin color in the
world. The other causes will be covered in the next section. However, ultraviolet radiations
(UVR) are the main factor causing pigmentation variation in the skin. They can produce
photodamage, erythema, mutations, vitamin D synthesis and tanning of the skin. Current
research on the mechanism of UV-induced pigmentation (tanning) suggests that UVR induced
DNA damage, and the mechanism for repair of these damages by a specialized endonuclease
increases the production of melanin [6, 9]. This quantity of produced melanin acts as a skin
protective barrier against the UVR by absorbing the UV photons [10]. Some research demon‐
strates that people who have more pigmented skin have less risk of developing skin cancer or
sunburn. Moreover, eumelanins, which are presented in high quantity in dark skin, are more
photoprotective than pheomelanins. They absorb free radicals generated in the cells by UVR,
thus preventing DNA damage [11].
1.1.1.1. Ethnic skin types
The different ethnic skin color worldwide depends on various factors such as UV exposition,
genetics, environmental factors and skin pigments [12]. Melanin is the principal pigment which
can affect skin color in several ways. The number of melanocytes, the melanogenic activity,
the melanin type, the size and the number of melanosomes and the distribution in the
epidermis can also affect the skin pigmentation [6]. In 2002, Alaluf et al. demonstrated that
Causasian skin was characterized by a low number of melanocytes (1 for 36 keratinocytes),
small melanosomes and light pigments such as pheomelanins while black skin was charac‐
terized by the presence of a higher number of melanocytes, larger melanosomes, a higher
quantity of melanin and more eumelanins [13]. It seems that the size of melanosomes is
important in the skin pigmentation because large melanosomes are found in the epidermis as
single particles, while small melanosomes tend to aggregate them. It could have the effect that
the large melanosomes are transferred to keratinocytes individually and thus, can absorb light
better than melanosomes transferred in complex [14].Their distribution in the epidermis is
equally very important and research demonstrated that in white skin, melanosomes are
Body
localization Functions
Skin Skin pigmentation
Photoprotection
Hair Hair pigmentation
Eyes Vision
Photoprotection
Eye pigmentation
Ears Hearing
Protection against high intensity noise
Central nervous system Scavenge toxic cations
Table 1. Melanocyte functions dependent on the body localization
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completely degraded before the stratum corneum while in dark skin, melanosomes are found
in this layer [15]. Therefore, all these characteristics contribute to ethnic groups their specific
skin color.
1.1.2. Other melanocytes
1.1.2.1. Hair and eye melanocytes
Melanocytes have a predominant role in skin color, but they have equally the same function
in hair and in eyes. In hair, they are localized in the bulb, at the bottom of the hair follicles, to
give the hair’s color. The same pigments found in skin, such as pheomelanin and eumelanin,
are also responsible for the different colors. Counter to skin melanocytes that rarely proliferate,
hair melanocytes can proliferate and differentiate in each hair cycle. This cycle includes the
growing phase (anagen) in which there is melanogenic activity and hair is pigmented. At the
end of this phase, the hair follicle regresses, the melanogenic activity decreases and the
melanocytes retract their dendrites to finally stop the pigmentation. These non-active mela‐
nocytes are replaced by new melanocytes, which are recruited from the pigment cell reservoir,
to restart a new hair cycle [16]. In eyes, there are two types of melanocytes: conjunctival and
uveal. The first type is localized in the conjunctiva and transfers melanin to conjuctival
epithelium while the second is localized in the iris and produces as well as stores melanin, but
it does not transfer melanin to any other cells [17]. The quantity or the type of melanin in uveal
melanocytes characterizes different eye colors. Such as in the skin, melanin contains in uveal
melanocytes may have a protective role for the eyes against UVR. However, few studies have
been conducted on this subject and uveal melanocytes remain unknown.
1.1.2.2. Ear and central nervous system melanocytes
Melanocytes have a well-known pigmentation function, but they also have an important role
in ears and in the central nervous system. Melanocytes in ears are located in the stria vascularis
of the cochlea, which is formed of three cell types: marginal cells, basal cells and intermediate
cells [18]. Intermediate cells are composed of two types of melanocytes, such as light cells that
are able to synthesize melanin, and dark cells that are incapable. They are necessary to the
normal function of ears, and damages or loss of these cells can cause the hearing loss [19]. Some
studies demonstrated that albino guinea pigs are more sensitive to high intensity of noise than
pigmented guinea pigs because of their low quantity of melanocytes [20]. In the nervous central
system, melanocytes are distributed on the meninges, particularly on the leptomeninges that
cover the brain. Their role in the organism is not yet well-determined, but it is known that
leptomeninge melanocytes have the capacity to capture toxic cations and free radical species
from the blood circulation [19].
1.1.3. Melanogenesis
Melanocytes originate in neural crest precursor cells: the melanoblasts. Melanoblasts migrate,
proliferate and differentiate into melanocytes to reach their destination, such as skin, eyes, hair,
meninges and ears [3]. Melanin is synthesized in these melanocytes in specialized lysosome-
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like organelles named melanosomes. These organelles have four stages of maturation in which
the melanosome begins unpigmented and ends pigmented [5]. The process of melanin synthe‐
sis is called melanogenesis and it needs three enzymes to assure its good working: tyroninase,
tyrosinase-related protein 1 (TRP1) and tyrosinase-related protein 2 (TRP2). These three enzymes
are necessary for the regulation of the melanogenesis, but tyrosinase is the limiting factor of this
pathway. It catalyzes the first two reactions of the biosynthesis of melanin that are necessary for
producing eumelanin and pheomelanin [21] while TRP1 and TRP2 are only involved in the
pathway of eumelanin [1]. Tyrosinase uses tyrosine, DOPA and 5,6-dihydroxyindole (DHI) as
substrate  to  produce  respectively  DOPA,  DOPA-quinone  and  DHI-melanins  (Figure  1).
Tyrosinase activity is regulated by some factors such as the pH, which needs to be optimal at 6.8
in melanosomes [22], and the melanocyte-stimulating hormone (α-MSH) secreted by melano‐
cytes. The α-MSH binds melanocortin receptor-1 (MC1R), which is expressed by melanocytes,
and triggers eumelanin pigments production whereas when α-MSH does not recognize MC1R,
pheomelanin pigments are generated [9]. Following this production of melanin, the melano‐
somes which have pigments are transported towards the end of the melanocyte dendrite by actin
and tubulin filaments. Then, melanosomes are transferred to keratinocytes (when it is skin
melanocytes). The mechanism of transfer is still unknown, but there exist some hypothesis about
this mechanism such as cytophagocytose [23], discharge melanin in the intercellular space [24],
or transfer by filopodia [25]. Once in keratinocyte, melanosomes are distributed around the
nuclei and, in response to UVR, they form a supranuclear melanin cap on the sun-exposed side
of the nuclei to protect DNA against the UVR damages [26]. Melanin pigments are degraded
with the keratinocytes when they move to the epidermal surface for their differentiation [11].
 Tyrosine 
DOPA 
DOPA-quinone 
Tyrosinase 
Tyrosinase 
Cysteinyl-DOPA 
Pheomelanins 
Glutathione 
orcysteine 
Eumelanins 
Leuco-DOPA-chrome 
DOPA-chrome 
DHICA DHI 
Indole 5,6 quinone Indole-5,6-quinone-2-carboxilic acid 
DHICA Eumelanins DHI Eumelanins 
TRP2 
TRP1 Tyrosinase 
Figure 1. Melanogenesis mechanism. TRP1: Tyrosinase-related protein 1; TRP2: Tyrosinase-related protein 2; DHI: 5,6-
dihydroxyindole; DHICA: 5,6-dihydroxyindole-2-carboxylic acid.
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1.2. Pigmentation diseases
Disorders in melanogenesis or in melanocytes can lead to different skin pigmentation pathol‐
ogies. Some disorders are characterized by a loss of skin pigmentation (hypopigmentation)
while others are recognized by the presence of dark plaques on the skin formed by an increase
of pigmentation (hyperpigmentation).
1.2.1. Hypopigmentation disorders
Hypopigmentation disorders affect skin pigmentation by the destruction of melanocytes, by
preventing development of melanocytes and by inhibiting or retarding melanin production.
Vitiligo is characterized by the first mechanism, piebaldism by the second, while oculocuta‐
neous albinism and tinea versicolor are characterized by the third mechanism [27]. These three
mechanisms lead to white macules/plaques on the skin because of the lack of melanin
pigments.
1.2.1.1. Vitiligo
Vitiligo is an autoimmune hypopigmentation disorder that affects approximately 1-2 % of the
population worldwide. This disease is characterized by the presence of white macules or
patches on the skin caused by the loss of functioning epidermal melanocytes [28]. Studies
suggest three principal hypotheses on the mechanisms of the melanocyte destruction: auto‐
immunity, neural and toxic hypothesis [29-30]. Autoimmune diseases such as thyroid diseases
[31] and diabetes mellitus [32] are often associated with vitiligo. These diseases cause defects
in the immune system, which can cause destruction of melanocytes and the loss of pigmenta‐
tion [29]. In addition, antibodies against melanocytes were found in serum of patient, and these
can engage the apoptosis of melanocytes when they are present [33]. T cells were also found
in perilesional vitiligo plaque biopsies and they are enriched with cytotoxicity against
melanocyte antigens [34]. The neural hypothesis is based on the contact of the melanocytes
with nerve endings in depigmented skin [35]. Neuropeptides and nerve growth factors such
as tumor necrosis factor-α, intercellular adhesion molecule-1 and interferon-γ were found in
perilesional skin, which suggest that nerves can have a role in destruction of melanocytes [30].
The toxic hypothesis suggests that the mechanism of natural protection of melanocytes is
defective. The melanocytes are unable to eliminate toxic molecules, and these are accumulated
in the cells [36]. More than these three mechanisms, the loss of melanocytes can be induced by
environmental factors, genetic predispositions [37], apoptosis or metabolic dysfunctions [38].
All these hypotheses are a good way to understand the pathology, but the one single mecha‐
nism of the melanocyte destruction in vitiligo is still unknown.
1.2.1.2. Piebaldism
Piebaldism is an uncommon hypopigmented disorder characterized by the presence of a
congenital white forelock and white macules on the extremities, forehead, frontal scalp and
ventral trunk [39]. This pathology is caused by mutations of loss-of-function in the KIT gene
that encodes for the stem cell growth factor receptor expressed in mastocytes and in melano‐
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cytes. When activated, KIT is essential to the development of melanocytes and stimulates their
proliferation [40]. These mutations prevent the development and the proliferation of melano‐
cytes, thereby causing white macules without melanocytes in skin and in hair.
1.2.1.3. Oculocutaneous albinism
Oculocutaneous albinism (OCA) is characterized by a disorder in the melanin synthesis in the
melanosome due to mutations in specific genes. Tyrosinase or other enzymes essential to the
melanogenesis are absent or dysfunctional, resulting in an incapacity in the melanosome to
synthesize melanin [41]. People affected by this disease have a complete or a partial loss of
pigmentation of the skin, hair and eyes, with the reduced pigmentation in eyes causing a
lowering of visual acuity. Four types of albinism exist, all characterized by mutation in a
different gene (Table 2). The most severe type is OCA1A, which is characterized by a complete
loss of hair and skin pigmentation, while eyes are light blue almost pink. People affected by
OCA1B can develop pigmentation on skin, hair and eyes, but they have a characteristic
temperature-sensitive pigmentation. Hairs on hands and feet can be pigmented, while body
hairs stay depigmented. The most common type worldwide is the OCA2 characterized by
various amount of cutaneous pigment and better vision than OCA1. OCA2 and OCA4 have
the same clinical characteristics, but differ in the responsible gene. People affected by OCA3
have characteristic red hair and reddish brown skin [42].
1.2.1.4. Tinea versicolor
Tinea versicolor is a common pigmentation disorder that can be characterized by round shaped
hypopigmented and hyperpigmented macules on the face, trunk and arms. These macules are
caused by the fungal infection, Malassezia, which is a genus normally found in the skin flora
[43]. Several factors play a role in the transformation of the benign form of the fungi to the
parasitic form. Fatty skin, exposure to sunlight, genetic predispositions, malnutrition and
corticosteroids can lead to development of lesions [44]. This lipophilic fungus metabolizes
various fatty acids and releases, as one of the metabolites, azelaic acid. This acid acts as an
inhibitor of tyrosinase, blocking the transformation of tyrosine in melanin pigment, resulting
in hypopigmented macules on the skin. Tinea versicolor is often found in young adults because
their sebaceous glands are very active due to the action for sex hormones [45]. The mechanism
of hyperpigmented macules is not as well-known as the previous mechanism. Some studies
demonstrate that melanosomes are larger in hyperpigmented macules than melanosomes in
normal skin and in white macules, but the cause of these enlarged melanosomes is still
unknown [14, 45-46].
1.2.2. Hyperpigmentation disorders
Hyperpigmentation disorders are characterized by darker skin that can be caused by an
increase of melanin synthesis or an increase of the melanocytes in the epidermis. “Café-au-
lait” macules, Addison’s disease and postinflammatory hyperpigmentation are characterized
by an increased production of melanin, while melanoma is the result of the two causes.
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1.2.2.1. “Café-au-lait” macules
“Café-au-lait” macules are characterized by light to dark brown spots of 1 to 20 cm on the skin
that can be of a congenital origin, or appear during life [47]. These spots are often the first sign
for the diagnosis of type 1 neurofribromatosis, a disorder caused by mutations in the NF1 gene,
and which can lead to benign and malignant tumors of the peripheral nerve sheath [48]. “Café-
au-lait” macules are caused by an increase of melanin in melanocytes and the presence of larger
melanosomes in keratinocytes, but the mechanism is still not well-known [49].
1.2.2.2. Malignant melanoma
Malignant melanoma is one of the most severe skin cancers affecting both men and women.
It begins in melanocytes which have been mutated and proliferates to form an irregular naevus,
a dark pigmented spot on the skin. In several cases, melanoma begins by forming a normal
mole, which is grows increasingly and becomes a metastatic melanoma [50]. Some factors can
affect the proliferation of the melanocytes such as genetic factors [51], environmental factors
[50], spontaneous mutations [52] and endocrine factors [53]. The most important factor playing
a role in this cancer is ultraviolet radiation exposure. UVR cause damages to DNA, the cell
usually being able to repair this by the transcription of one of the tumor-suppressor genes, for
instance, p53. The protein produced by p53 genes stops the cycle cell, preventing the repro‐
duction of DNA mutations. When there are mutations in the p53 gene, the cell cycle can not
be stopped and mutations in DNA are reproduced and accumulated in the cell that will lead
to a hyperproliferation of melanocytes and a melanoma [54]. Other genes such GADD45,
PTCH, p16, and oncogenes such as Bcl-2, ras, c-fos can be involved in the pathway of UV-
induced melanoma [55].
1.2.2.3. Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation occurs after cutaneous inflammation or injury and
causes dark plaques on skin. It can affect all types of skin, but dark-skinned people are mostly
affected, especially after acne [56]. Hyperpigmented plaques are caused by an overproduction
of melanin or an irregular distribution of melanin in the epidermis [57]. The exact mechanism
is not well-known, but it has been shown that cytokines, chemokines, inflammatory mediators
such as leukotrienes, prostaglandins E2 and D2, thromboxane-2, interleukin IL-1 and IL-6,
TNF-α and some others can stimulate melanocyte activity and promote the production of
melanin [58].
OCA type Responsible gene
OCA1 Tyrosinase
OCA2 P gene
OCA3 TRP1
OCA4 SLC45A2
Table 2. Gene responsible of oculocutaneous albinism (OCA) different types. TRP1: Tyrosinase-related protein 1
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1.2.2.4. Addison’s disease
Addison’s disease, also called adrenal cortical insufficiency, is a rare endocrinal disorder that
in more than 50 % of cases is caused by an autoimmune disease. The adrenal glands can not
produce enough steroid hormones, resulting in a deficiency in corticosteroids [59]. One of the
first indicator symptoms of this disorder is the development of a diffuse hyperpigmentation
of the skin (DHP). DHP is caused by the increase of adrenal corticotrophic hormone (ACTH)
in the circulation, which has the same precursor molecule to α-MSH, the melanocytes-
stimulate hormone. Considering that ACTH has approximately the same composition as α-
MSH, they will have the same function in the organism: stimulate melanin production [60].
This production of melanin gives people affected by Addison’s disease a brown skin, intensi‐
fied at the sites that are exposed to light and pressure, in the skin folds, lines of the hands,
nipples and areas of scarring [59].
1.3. Available treatments
1.3.1. Cosmetic treatments
Make up, topical dyes and tanning cream are frequently used to cover up undesirable plaques
caused by different pigmentation diseases. Cosmetics treatments are practiced to improve the
quality of live for young people that can not undergo surgeries because it is not recommended
before adulthood. In vitiligo and in piebaldism, dihydroxyacetone (DHA), the browning
ingredient in tanning formulations, can be used to camouflage depigmented lesions. DHA
polymerizes amino acid of the skin creating pigmentation similar to UV tanning and covering
the depigmented plaques of vitiligo and piebaldism patients [61]. However, no melanin
pigment is produced and DHA is much less protective against UV than melanin [62]. Some
other tanning products can be useful for people affected by a hypopigmentation disorder,
while for the hyperpigmentation disorders, patients may use cosmetics such as make-up to
cover up their lesions. In postinflammatory hyperpigmentation, scars of acne are frequently
concealed with makeup and allow affected people to have a better quality of life [56].
1.3.2. Therapeutic treatment
1.3.2.1. Hypopigmentation disorders
Therapeutic treatments, unlike cosmetic treatments, are durable and usually treat the disease.
For hypopigmentation disorders, treatment objectives are to increase the production of
melanin and the quantity of melanocytes. In vitiligo, the most popular treatment is psoralen-
UVA phototherapy (PUVA). This treatment uses the extract of plants such as 8-methoxypsor‐
alen (8-MOP), 5-methoxypsoralen (5-MOP), and a synthetic compound, trisoralen (TMP).
These compounds can be used orally or in topical agents by patients, after which, they have
to be exposed to sunlight or UVA radiation [36]. PUVA affects skin by increasing the number
and the activity of melanocytes in the epidermis resulting in an augmentation of the pigmen‐
tation [63]. Another attractive treatment for vitiligo is immunomodulators. It is suggested that,
in this disease, T cells play a role in destruction of melanocytes, and researchers are trying to
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find immunomodulators that will inhibit them. Cyclosporine is one of them, and prevents the
activation of T cells by inactivation of the calcineurin, which is a regulate transcription factor
of T cells [64]. Levamisole is another immunomodulators that has been studied for vitiligo
treatment, and its sound effectiveness has been demonstrated [65]. The mechanism of action
of this compound is not well-known, but no side effect was reported. Vitiligo and piebaldism
can be treated with surgeries such as suction blister grafting [36, 66], noncultured melanocytes
transplantation [67], cultured epidermis grafting [68] and autologous minigrafting [30]. In
tinea versicolor, considering that the disease is caused by a fungus, the principal treatments
are topical or oral antifungal agents. Nonspecific topical antifungal agents exist that do not
directly affect the fungus, and specific topical antifungal agents that specifically affect the
fungus. The most popular nonspecific agents are selenium sulfide and benzol peroxide which
chemically remove the infected tissue and prevent a recurrence. Azoles, terbinafine and
ciclopiroxolamine are some groups of drugs that are frequently used as specific topical agents
to directly attack the fungus [69]. Most of these agents can be taken orally as specific topical
agents, and are more effective and simpler for the patient [43]. For oculocutaneous albinism,
unfortunately, no treatments are reported to be effective for repigmentation of affected people.
1.3.2.2. Hyperpigmentation disorders
In hyperpigmentation disorders, therapeutic treatments have to diminish the melanin
production and the quantity of melanocytes. “Café-au-lait” macules are mainly treated with
lasers. These lasers must emit a specific wavelength that will be well-absorbed by the chro‐
mophore being treated. In this disease, the referred chromophore is the melanin that has a
well-absorbance at 694 nm [70]. Melanin pigment absorption decreases when the wavelength
of the laser increases, and thus in this treatment, it is important to choose the appropriate
wavelength [71]. For malignant melanoma, several treatments are available, but research for
more effective treatments still continue. Currently, the main treatment is the excision of the
malignant melanoma, with excision of a large region around the site to make sure that no
cancer cell remains. If there are metastases in many other organs, surgery can rarely treat it.
In these cases, patients resort to chemotherapy, using drugs which will kill cancer cells by
passing into the bloodstream. If the melanoma is recurrent, patient will undergo radiation
therapy, high energy rays that cause damage to cancer cells and inhibit their growth, prevent‐
ing the spread of other malignant melanomas. Immunotherapy is also used for the treatment
of this cancer. This therapy consists of strengthening the immune system of the patient so that
he can fight against cancer cells. Cytokines such as interpheron-α, interleukin-2 and TNF can
be used to stimulate the patient’s immunity [72-73]. Unlike the previous two diseases,
postinflammatory hyperpigmentation is principally treated with the utilisation of medications
such as hydroquinone, mequinol, retinoids, azelaic acid and ascorbic acid [56]. Hydroquinone,
azelaic acid and mequinol all affect tyrosinase to inhibit the melanin production, but not in the
same way. Hydroquinone and azelaic acid will interfere with tyrosinase, while mequinol acts
like a competitive substrate of tyrosinase [74]. Retinoids such as tretinoin and tazatorene help
the penetration of other medications through the skin barrier by causing skin irritation and
inducing the apoptosis of mature melanocytes [75]. Ascorbic acid suppresses the melanin
production by reducing the formation of quinones, creating a lack in the melanogenesis process
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[76]. However, postinflammatory hyperpigmentation can be treated by a peeling surgery, a
technique that uses chemical products for destruction of a part of the dermis and/or the
epidermis [77]. Finally, diffuse hyperpigmentation in Addison’s disease is usually treated with
mineralocorticoid and glucocorticoid [78]. These two corticosteroids will compensate for the
lack of corticosteroids, reduce the production of ACTH, and thus, reduce the production of
melanin pigments. Considering that it is a rare disease, treatments are not very abundant. The
development of pigmented skin models could be useful for studying unknown mechanisms
involved in these disorders, and for developing more relevant treatments with few side effects.
2. Challenges for the development of pigmented skin models
2.1. Tissue engineering
It is known that there is a real need for human organs available for transplantations [79]. Each
year, people die while they are waiting for a compatible organ. Just in Canada, in 2011, a person
needing an organ had a 30 to 40% probability of not receiving it [80]. Moreover, there are some
problems with allogeneic grafts, such as problems of incompatibility and reject preoccupa‐
tions. To get rid of these problems, a new approach emerged at the end of the 1980s [81]. This
approach, called tissue engineering, is a science that combines both biology and engineering
expertise. Its goal is to develop biological substitutes for maintaining, repairing or regenerating
human organs or tissue, such as skin [82-83].
2.2. Skin substitutes
Skin substitutes are useful in different fields. They can be grafted onto patients suffering from
severe burns or chronic wounds such as skin ulcer [84-85]. They can also be used for funda‐
mental research to analyze skin functional mechanisms. Moreover, skin substitutes can be used
for cosmetic testing to replace animal testing [86]. While skin is the interface tissue between
human body and exterior environment, it is an organ particularly exposed to chemical and
mechanical wounds and to pathological agents. Furthermore, it is an important organ in area
and complexity both in structural and functional ways [87]. Consequently, to regenerate a
human skin with all its functionality is a big challenge.
2.2.1. Skin substitute characteristics
In recent years, many skin substitutes have been reported, becoming more and more similar
to natural human skin, but different from each others, and still not perfectly simulating skin
functionality. Those substitutes can be characterized by different factors. Provenance of cells
used to produce the substitute can be either allogeneic, xenogeneic or autologous. Presence of
autologous cells allows reduction of incompatibility and graft reject problems [88]. The
purpose of substitutes can also vary between a permanent, semi-permanent or temporary use
[83]. Depending on the use wanted, complexity of substitutes will change and can be either
monolayered or bilayered. As there is no perfect substitute that has been developed to this
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day, research and development on skin substitutes are still very current. Many aspects must
be considered in the elaboration of a skin substitute so that it will be as close as possible to
human skin. First, histological properties must be evaluated. Indeed, a perfect skin substitute
must have both dermis and epidermis, with an epidermis well-differentiated and the presence
of all its four principal layers: stratum basale, stratum spinosum, stratum granulosum and stratum
corneum. Moreover, skin structure is important and can be evaluated by the expression or not
of different markers and their localization. Furthermore, skin plays an important role as a
protective barrier against chemical, biological and mechanical aggression. Consequently, the
presence of this barrier functionality is important. A method to evaluate the barrier efficacy is
to perform permeability analysis. Finally, stratum corneum lipid organization is also important
in skin barrier functionality. This organization must be well-structured and features can be
analyzed by ATR-FTIR [88]. One of the lacks in the currently available skin substitutes is the
absence of melanocytes that lead to a hypopigmentation of the skin where the substitute is
grafted. While melanocytes are part of the skin protection against UV irradiations, the lack of
this molecule in skin substitutes can become problematic for the patient, beyond the cosmetic
preoccupations [89]. Therefore, there is a need for developing skin substitutes with melanocyte
cells. Moreover, incorporation of ill melanocytes in skin models allows the study of melanocyte
skin diseases such as melanoma. While tests on animal skin are not always representative of
human skin and can be ethically problematic, the development of pigmented skin models
becomes a real need.
3. In vivo and in vitro pigmented skin models
Human melanocytes have been cultured selectively for two decades when, in 1982, Eisinger
and Marko published their work on selective proliferation of human melanocytes. Their
selective culture was based on the proprieties of phorbol ester. Indeed, at a certain concentra‐
tion, this compound is toxic for keratinocytes, but not for melanocytes. By adding it to an
epidermal cell solution, it allows the selective proliferation of melanocytes only [90]. In 1986,
Topol et al. went further and reported the first pigmented human skin equivalent. This
equivalent consisted of human neonatal melanocytes plating onto a dermal skin substitute
with keratinocytes. They were added before those cells overgrew the dermal equivalent [91].
Since that year, many other models have been developed.
3.1. In vivo models
3.1.1. Spontaneous and induced mutations
Spontaneous mutation models can be use to study some diseases when the mutations have
similarity with human diseases. In melanocyte skin diseases, there are not many spontaneous
mutation models available. One of them was developed in 1981 by Smyth which proposed a
chicken model to study human vitiligo [92]. Indeed, he developed a mutant line of chickens
characterized by a higher than normal spontaneous postnatal cutaneous amelanosis. This
affection has similarity to human vitiligo. They are both a consequence of melanocyte de‐
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struction. Those chickens are called “chickens of the autoimmune delayed-amelanotic” (DAM)
or “Smyth chickens”.
In melanomas studies, spontaneous mutations on mice are rare because, even if some chemical
agents can induce them, it takes a long time, and the melanomas are not very representative
of human ones, with the frequent absence of metastases that are frequent in human [93]. Most
of the models found in the literature use other animals. An example is Millikan et al. which
proposed in 1974 a Sinclair swine model to study pigment tumors [94]. Lesions developed by
those swine are similar histologically and clinically to some different human tumors. Indeed,
they show flat lesions that can be compared to human junctional neavus and elevated lesions
similar to human compound neavus. Some other lesions found in swine are raided blue
tumors, the counterpart of human blue neavus, peripheral depigmentation, the counterpart of
vitiligo, and ulcerative tumors, the counterpart of melanoma. Previously, in 1966, Cherno‐
zemski has proposed a Syrian hamster model which presented spontaneous or induced by
DMBA melanomas [95]. DMBA was also used to induce melanomas on Guinea pigs by Clark
et al. ten years later [96]. Clark et al. have reproduced Edgcomb’s and Mitchelich’s work of 1963
and had shown that tumors in guinea pigs have some similarities with those in humans, but
are not histogenetically the same. In 1989, Setlow et al. reported a platyfish-swordtail hybrid
model susceptible to melanoma when exposed to UV radiations [97]. This fish had already
been used by other authors in the past such as Anders et al. who used it in 1984 for melanoma
research [98]. Setlow, in his work, studied different strains of this fish and their response to
some UV wavelengths to find two that were susceptible to melanomas under UV irradiations.
Fish of those two strains developed melanomas that were quite similar to the human ones. The
principal difference was the presence of melanophores in fish melanomas. In vertebrates,
melanophores represented the last stage of pigmented cells differentiation. The same year, Ley
et al. also reported an animal model of melanomas induced by UV radiations using South
American opossum [99]. In their study, they also used the concept of photoreactivation repair
pathway for DNA damages to investigate pyrimidine dimer’s implication in melanoma
induction. Their research allowed them to make two principal conclusions: first, they con‐
cluded that UV radiations can be used to induce malignant melanoma; second, they came to
the conclusion that pyrimidine dimer is involved in melanoma formation, and that the
radiations induced DNA damages. Reported spontaneous models of melanoma have been less
and less frequent in the recent years probably as a result of the improvement of science in
different fields such as gene modifications and in vitro models.
3.1.2. Transgenic models
Transgenic  animals  can be useful  for  mimicking some human diseases  such as  melano‐
ma.  In  1991,  Bradl  et  al.  reported  a  transgenic  mouse  with  the  simian  virus  40  (SV-40)
controlled by a tyrosinase promoter [93] that promotes ocular and cutaneous melanomas.
The melanomas reported were histopathologically the same as their human counterparts.
One  year  later,  Iwamoto  et  al.  also  reported  a  transgenic  mouse  model  for  studying
melanocyte tumors. Their model consisted of a mouse metallothionein promoter enhanc‐
er coupled to a ret oncogene inductor [100]. They developed four independent mouse lines:
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three of those lines were well-predisposed to developing melanocytic tumors, and the other
one reported an acceleration of melanogenesis with no clear proliferative disorders. In 1994,
Klein-Szanto et al. also used the SV40 driven by tyrosinase promoter to develop a transgenic
mouse  model.  Their  model  allowed  them  to  study  the  induction  of  malignant  skin
melanomas  by  short  ultraviolet  radiation  exposure  and  without  chemical  carcinogen
application [101]. Inbred line choice and other factors such as the age of the mice and the
intensity  of  the  UV  treatment  can  be  modified  in  the  protocol  to  improve  melanoma
induction. In 1997, Takayama et al.  proposed a new transgenic mouse model,  also using
metallathionein  promoter  driving,  this  time  an  hepatocyte  growth  factor/scatter  factor
(HGF/SF) [102]. They wanted to study the oncogenic role of those factors. Their transgen‐
ic mice developed a large variety of tumors, including melanoma. Some tumors, includ‐
ing this one, overexpressed HGF/SF. The same year, Chin et al. reported another transgenic
mouse  model  using  a  different  gene.  Indeed,  their  model  consisted  of  H-ras  driven  by
tyrosinase  promoter  with  INK4a  knockout  mice  [103].  Their  studies  allowed  them  to
conclude that development of melanoma can be accelerated by both the loss of INK4a allele
and the activation of  Ras.  In  2009,  Goel  et  al.  reported a  BRAFV600E transgenic  mouse
[104]. Indeed, in more than half melanoma cases, there is presence of a mutation that affects
BRAF, a protein activated by Ras. Transgenic mice presented benign melanocytic hyperpla‐
sia of which progression to the melanoma stage depended on BRAF expression. In 2011,
Meyer  et  al.  used  ret  transgenic  mice  to  study  melanoma  evolution.  They  also  studied
inflammatory  tumor  microenvironment  when  there  is  enrichment  of  myeloid-derived
suppressor  cells  (MDSCs).  They  concluded  from  their  studies  that,  before  starting  an
immunological treatment for melanoma, the immune status should be controlled and the
immunosuppressive microenvironment should be neutralized [105].  However,  transgenic
models are not the best for mimicking some cancers such as melanoma because, such as
spontaneous mutations, they present a lack of metastase production. Indeed, it is known
that the importance or not of metastases in large amount is crucial for the patient’s survival.
By  consequence,  it  is  often  a  target  in  treatment  development  and so  their  presence  is
important to have a valuable model.
3.1.3. Xenotransplantation models
Another type of model that can be used to study human melanoma consists of xenotrans‐
plantation of human skin onto an animal. For models on mice, three different types of this
animal  are  mainly  used:  athymic  nude  mice,  severe  combined  immunodeficient  mice
(SCID) and spontaneous AGR129 mice models. The immune systems of those mice differ
from those of  normal  mice  so  that  their  immunological  potential  is  decreased.  Athymic
nude mice do not have T cells because of the absence of a thymus. SCID mice do not have
either T cells, and are also deficient of B cells. AGR129 mice do not have either T or B cells
as  SCID  mice,  and  also  have  immature  natural  killer  cells  [106].  In  1993,  Juhasz  et  al.
proposed a xenotransplantation model of  human skin grafted onto either nude or SCID
mice. Beforehand, human melanomas were injected onto the human skin graft [107]. This
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model can allow reproduction of human melanomas and their metastases because tumour
cells invaded human vessels, and in more than half case, metastases were found in lungs.
In 1998 Atillasoy et al.  proposed another model for studying UV irradiations and chemi‐
cal carcinogen implication in skin melanoma development. Their model consisted of human
newborn foreskin  grafted onto  RAG-1 mice.  Mice  were  separated into  four  groups and
received different treatments. While the first group was the control group and received no
treatment,  the  second received a  treatment  of  DMBA,  a  chemical  carcinogen.  The  third
group received UVB irradiations and the last one, both DMBA and UVB irradiations [108].
Only DMBA treatment  was not  conclusive,  as  the only impact  was the development of
melanocytic hyperplasia in 16%. UVB only treatment was a little better as it caused solar
lentigo  in  23%  and  melanocytic  hyperplasia  in  68%.  Combined  treatment  caused  solar
lentigo in 38% and melanocytic hyperplasia in 77% and was the only one that generated
melanoma  in  2.1%  after  15  months.  This  is  representative  of  melanoma  incidence  in
Caucasian Americans that is 1.4%. In the last years, xenotransplantation models were also
used to test different treatments. For example, in 2010, Schicher et al. used a xenotransplan‐
tation model of a SCID mouse with a human melanoma graft to test treatment of Erloti‐
nib combined with some chemotherapeutics agents [109]. Erlotinib is a treatment already
used for non small  cell  lung cancer.  The melanomas treated with a combined treatment
showed a higher reduction than those only treated with chemotherapeutic agents.
3.1.4. Other models
Other testing systems that  can be used are injection of  mouse melanoma into mice.  For
that, some mouse melanoma cell lines have been produced. One of these lines originated
from one of the rare spontaneous melanomas in mice, an event that occurred on the ear
of a C57BL/6 mouse in 1954. It was Fidler et al., who at the beginning of the 1970s really
set up the line known as B16 melanoma cell line [110]. Those murine melanoma cells can
be used for studying melanoma treatments as reported by some authors. For example, in
2002,  Lucas  et  al.  injected  B16  melanoma in  C57BL/6  mice  in  order  to  test  injection  by
electroporation of interleukin-12 [111]. They tested an intratumoral and an intramuscular
treatment. While the first one was useful for treating tumour in 47% of the cases, the second
one was not conclusive. They also tried those two treatments in a nude mouse model, but
neither  the  intratumoral  or  the  intramuscular  treatment  worked.  Those  results  allowed
them to conclude that T cells probably have a role in the melanoma regression, at least in
this  model.  The  same  year,  Garcia-Hernandez  et  al.  investigated  on  the  implication  of
interleukin-10 in the promotion of B-16 melanoma growth [112]. This study allowed them
to conclude that  IL-10 seems to have a role in this  promotion in three fields:  first,  they
simulate  the  proliferation  of  the  tumour-cells;  second,  they  have  implications  for  the
angiogenesis  process  and  third,  they  are  implicated  in  the  immunosuppression.  B16
melanoma cells can therefore be useful to many types of studies.
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3.2. In vitro models
3.2.1. Monolayers
Monolayer models are characterized by the culture of one cell type, which has previously been
extracted from a skin biopsy. Cells can be extracted from normal or lesional skin such as cells
of skin affected by hypo- and hyperpigmentation disorders. Monolayer models are useful for
studying melanocyte properties and testing different conditions or drugs. In 2008, in a
comparative study of melanocytes culture and melanocytes-keratinocytes co-culture, Liu et
al. demonstrated the effect of melanogenic stimulators (α-MSH and L-tyrosine) and inhibitors
(arbutin and hydroxybenzyl alcohols (HBA)) in the two conditions [113]. Results showed that
α-MSH and L-tyrosine increased the melanin content of melanocytes, and that the increase
was better in the co-culture with keratinocytes. 4HBA and arbutin inhibit the melanogenesis
in the two conditions, but, in co-culture, the inhibition was much better than in melanocytes
alone. These results suggest that cytokines released by keratinocytes can have an effect on the
regulation of melanin synthesis, and that the co-culture model has interesting properties for
testing drugs related to the treatment of pigmentation disorders. In the same vein as Liu et
al.,Criton et al. tested 22 N-hydroxy-N-phenylthiourea and N-hydroxy-N-phenylurea ana‐
logues, which could inhibit tyrosinase activity and reduce melanin synthesis on melanocyte
culture [114]. Results showed that compound 1 inhibits tyrosinase and reduces 78 % of melanin
synthesis. It is a promising candidate for the treatment of hyperpigmentation disorders to
replace whitening agents that have undesirable effects. These studies demonstrate that
monolayer models allow testing of several conditions, and the possibility of observing
melanocytes behavior in some pigmentation disorders.
3.2.2. Collagen gels
Unlike monolayer models, which are composed of only one cell type, collagen gel models allow
formation of a dermis on which more than one cell types can be seeded. Globally, for the
construction of a pigmented equivalent with collagen gel, fibroblasts, keratinocytes and
melanocytes are extracted from a skin biopsy and are cultured separately. Fibroblasts are
seeded onto the collagen gel, then, after few weeks of culture, keratinocytes and melanocytes
can be seeded onto fibroblasts and collagen matrixes [115]. These types of equivalent that
contain various cell types are useful for studying the interactions between keratinocytes and
melanocytes and understanding different mechanisms of pigmentation disorders. Recently,
Duval et al. developed a pigmented skin model using collagen, such as a dermal matrix that
is very representative of normal human skin with melanocytes [116]. They demonstrate that
their model has a functional pigmentary system by the presence of melanocytes well-devel‐
oped with melanosomes, the expression of tyrosinase, TRP1 and TRP2, the transfer of mela‐
nosomes containing melanin to keratinocytes and the stimulation of melanin synthesis by α-
MSH. This model has most of the normal human skin melanocyte characteristics [9] and seems
to be an interesting pigmented skin model for studying cell interactions of the pigmentary
system. A study with this type of skin model has observed the response of melanocytes after
UV radiation [117]. Archambault et al. demonstrated by a comparative study of monolayer
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melanocyte culture and pigmented skin equivalent that melanocytes have a better capacity for
surviving UVR than melanocytes in culture. These results suggest that keratinocytes and
fibroblasts secrete factors that enhance melanocytes survival and migration, which could
explain UVR-induced pigmentation by melanocytes. Unlike other teams, Freeman et al.
elaborated another technique of culture with collagen gels [118]. They put a complete skin
biopsy, which was affected by a melanoma, onto a collagen gel that contained fibroblasts. This
technique allowed conservation of the in vivo properties of the melanoma and observation of
the proliferation and other characteristics in vitro. All of these models composed with a collagen
matrix are representative of human skin, and are effective for the study of pigmentation
disorders. However, collagen models may not be useful for testing drugs, because they can be
absorbed by the collagen and a higher quantity of drugs must be used [119].
3.2.3. De-Epidermized Dermis (DED)
Such as collagen gels, DED allowed the construction of pigmented skin equivalent that
reproduced human skin for studying the pigmentary system. Unlike collagen gels, this method
has a native extracellular matrix and a basal membrane that facilitates melanocyte adhesion.
Principally, DED preparation is very similar. From a skin biopsy, the epidermis is removed
and the dermis is incubated in saline solution or undergoes freezing-thawing cycles to kill cells
[120]. After this treatment, the dermis remaining is called a dead de-epidermized dermis, and
is ready to be seeded by keratinocytes and melanocytes. In 1993, Todd et al. used this model
to demonstrate the effect of UV radiation on a pigmented equivalent [121]. They demonstrated
that, after UV radiation, there is an increase of TRP1 activity, an increase of pigmentation and
an increase of DOPA-positive melanocytes such as observed in vivo. In 2000, for a better
understanding of melanoma invasion, Dekker et al. developed and characterized a DED skin
equivalent with four types of melanoma cells [122]. They observed the expression of different
integrins that play an important role in the behavior of melanoma cells. Their model is a useful
tool for studying melanoma and other mechanisms involved in this cancer. In 2007, Cario-
André et al. developed a DED skin model with normal and non-lesional vitiligo cells to
understand if the loss of melanocytes in vitiligo is caused by a detachment of melanocytes due
to stress factors [123]. The model with non-lesional vitiligo cells contains less melanocytes than
the model with normal cells, and hydrogen peroxide and epinephrine could be the cause of
the detachment of melanocytes. Todd, Dekker and Cario-André models demonstrated that de-
epidermized dermis is an interesting model for studying different pigmentation disorders and,
in comparison with collagen gels, DED produced an epidermis, which is closer to the native
epidermis than collagen gels [124].
3.2.4. Commercial models
Commercial in vitro skin models have been developed to reduce tests on animals, replace
animal models and refine methodologies. For the cosmetic industry, it allows testing of the
toxicity of their products and their pharmaceutical effects on a complete human epidermis and
dermis. Several companies produce skin models and some of them produce equally pigmented
skin models that are useful for testing photoprotection, whitening agents and repigmentation
Regenerative Medicine and Tissue Engineering774
products. The list of the main commercial pigmented skin models and their principal features
is presented in Table 3.
Models Type of models
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SkinEthicTM Cells seeded on a polycarbonate filter x x [125]
MelanoDermTM Cells seeded on a collagen gels x x [126]
StratiCellTM Cells seeded on a polycarbonate filter x x (only 2)
Melanoma skin modelTM Cells seeded on a collagen gels x [127]
Table 3. Different commercial pigmented skin models
4. Conclusion
Melanocytes are underestimated cells that are more than pigmentation cells. They protect the
skin against environmental factors and they are necessary for sight and hearing. However,
melanocytes can also be the cause of some skin disorders and cancer. Even more mechanisms
involved in pigmentation disorders remain unknown and need to be elucidated upon in order
to give affected people a better quality of life. In vitro pigmented skin substitutes produced by
tissue engineering and in vivo models are useful tools for understanding these mechanisms
and developing appropriated treatments or drugs.
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